Browse > Article
http://dx.doi.org/10.1038/s12276-018-0181-3

Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling  

Xiao, Yongtao (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University)
Zhou, Kejun (Shanghai Institute of Pediatric Research)
Lu, Ying (Shanghai Institute of Pediatric Research)
Yan, Weihui (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University)
Cai, Wei (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University)
Wang, Ying (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University)
Publication Information
Experimental and Molecular Medicine / v.50, no.11, 2018 , pp. 14.1-14.14 More about this Journal
Abstract
The link between antibiotic treatment and IF-associated liver disease (IFALD) is unclear. Here, we study the effect of antibiotic treatment on bile acid (BA) metabolism and investigate the involved mechanisms. The results showed that pediatric IF patients with cholestasis had a significantly lower abundance of BA-biotransforming bacteria than patients without cholestasis. In addition, the BA composition was altered in the serum, feces, and liver of pediatric IF patients with cholestasis, as reflected by the increased proportion of primary BAs. In the ileum, farnesoid X receptor (FXR) expression was reduced in patients with cholestasis. Correspondingly, the serum FGF19 levels decreased significantly in patients with cholestasis. In the liver, the expression of the rate-limiting enzyme in bile salt synthesis, cytochrome P450 7a1 (CYP7A1), increased noticeably in IF patients with cholestasis. In mice, we showed that oral antibiotics (gentamicin, GM or vancomycin, VCM) reduced colonic microbial diversity, with a decrease in both Gram-negative bacteria (GM affected Eubacterium and Bacteroides) and Gram-positive bacteria (VCM affected Clostridium, Bifidobacterium and Lactobacillus). Concomitantly, treatment with GM or VCM decreased secondary BAs in the colonic contents, with a simultaneous increase in primary BAs in plasma. Moreover, the changes in the colonic BA profile especially that of tauro-beta-muricholic acid ($T{\beta}MCA$), were predominantly associated with the inhibition of the FXR and further altered BA synthesis and transport. In conclusion, the administration of antibiotics significantly decreased the intestinal microbiota diversity and subsequently altered the BA composition. The alterations in BA composition contributed to cholestasis in IF patients by regulating FXR signaling.
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hudgins, J. D., Goldberg, V., Fell, G. L., Puder, M. & Eisenberg, M. A. Reducing time to antibiotics in children with intestinal failure, central venous line, and fever. Pediatrics 140, e20171201 (2017).   DOI
2 Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011).   DOI
3 Musso, G., Gambino, R. & Cassader, M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu. Rev. Med. 62, 361-380 (2011).   DOI
4 Marchesi, J. R. et al. The gutmicrobiota and host health: a new clinical frontier. Gut 65, 330-339 (2016).   DOI
5 Canfora, E. E., Jocken, J. W. & Blaak, E. E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577-591 (2015).   DOI
6 Cox, L. M. & Blaser, M. J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 11, 182-190 (2015).   DOI
7 Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, (Suppl 1), 4554-4561 (2011).   DOI
8 Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).   DOI
9 Vrieze, A. et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60, 824-831 (2014).   DOI
10 Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225-235 (2013).   DOI
11 Lacaille, F. et al. Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. J. Pediatr. Gastroenterol. Nutr. 60, 272-283 (2015).   DOI
12 Wessel, J., Kotagal, M. & Helmrath, M. A. Management of Pediatric Intestinal Failure. Adv. Pediatr. 64, 253-267 (2017).   DOI
13 Xiao, Y. T., Cao, Y., Zhou, K. J., Lu, L. N. & Cai, W. Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure. Sci. Rep. 6, 39264 (2016).   DOI
14 Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241-259 (2006).   DOI
15 Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174 (2003).   DOI
16 Jia, W., Xie, G. & Jia, W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111-128 (2018).   DOI
17 Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744 (2000).   DOI
18 Chiang, J. Y. Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966 (2009).   DOI
19 De Fabiani, E. et al. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J. Biol. Chem. 276, 30708-30716 (2001).   DOI
20 Green, R. M., Beier, D. & Gollan, J. L. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111, 193-198 (1996).   DOI
21 Kosters, A. & Karpen, S. J. The role of inflammation in cholestasis: clinical and basic aspects. Semin. Liver Dis. 30, 186-194 (2010).   DOI
22 Botham, K. M. & Boyd, G. S. The metabolism of chenodeoxycholic acid to betamuricholic acid in rat liver. Eur. J. Biochem. 134, 191-196 (1983).   DOI
23 Gadaleta, R. M., Cariello, M., Sabba, C. & Moschetta, A. Tissue-specific actions of FXR in metabolism and cancer. Biochim. Biophys. Acta 1851, 30-39 (2015).   DOI
24 Pereira-Fantini, P. M. et al. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. J. Hepatol. 61, 1115-1125 (2014).   DOI
25 Mutanen, A., Lohi, J., Heikkila, P., Jalanko, H. & Pakarinen, M. P. Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. J. Hepatol. 62, 1391-1397 (2015).   DOI
26 Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J. & Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678-693 (2008).   DOI
27 Meier, P. J. & Stieger, B. Bile salt transporters. Annu. Rev. Physiol. 64, 635-661 (2002).   DOI
28 Uppal, H. et al. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41, 168-176 (2005).   DOI
29 Zollner, G., Marschall, H. U., Wagner,M. & Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251 (2006).   DOI
30 Trauner, M. & Boyer, J. L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671 (2003).   DOI
31 Gura, K. M. et al. Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. J. Parenter. Enter. Nutr. 42, 455-462 (2018).
32 Stueck, A. E. Intestinal failure-associated liver disease: risks and regression. Liver. Int. 38, 35-37 (2018).   DOI
33 Wang, P. et al. Alterations in intestinal microbiota relate to intestinal failureassociated liver disease and central line infections. J. Pediatr. Surg. 52, 1318-1326 (2017).   DOI
34 Kim, I. et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664-2672 (2007).   DOI
35 Al-Shahwani, N. H. & Sigalet, D. L. Pathophysiology, prevention, treatment, and outcomes of intestinal failure-associated liver disease. Pediatr. Surg. Int. 33, 405-411 (2017).   DOI
36 Ridlon, J. M., Kang, D. J., Hylemon, P. B. & Bajaj, J. S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332-338 (2014).   DOI
37 Kisiela, M., Skarka, A., Ebert, B. & Maser, E. Hydroxysteroid dehydrogenases (HSDs) in bacteria: a bioinformatic perspective. J. Steroid Biochem. Mol. Biol. 129, 31-46 (2012).   DOI
38 Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999).   DOI